Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.41M | $-67.85M | $-0.23 |
| 2024 | $4.05M | $-54.05M | $-0.20 |
| 2023 | $6.04M | $-63.08M | $-0.26 |
| 2022 | $2.49M | $-86.80M | $-0.40 |
| 2021 | $0.00 | $-58.37M | $-0.30 |
Social Signal Score
Earnings
Wed, Nov 4(in 3 months)
Consensus estimate $-0.06 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.07 vs $-0.05miss
- Tue, May 5$-0.06 vs $-0.05miss
- Wed, Mar 4$-0.06 vs $-0.06beat
- Wed, Nov 5$-0.07 vs $-0.06miss
- Fri, Aug 1$-0.05 vs $-0.06beat
- Fri, May 9$-0.05 vs $-0.06beat
Estimates and results for OCGN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
OCGNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsmarketbeat.com·6h ago·Neutral
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts Ocugen NASDAQ: OCGN is positioning its ophthalmology gene therapy portfolio around treatments for inherited retinal diseases and dry age-related macular degeneration, with pivotal-stage programs in retinitis pigmentosa, Stargardt disease and geographic atrophy, Chairman, CEO and Co-Founder Shankar Musunuri said during a Canaccord discussion.
View source ↗